Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome.

Abstract:

:Follicular lymphoma is characterized by a good response to immunochemotherapy (ICT). However, a small percentage of patients responds poorly to treatment and seems to have a worse outcome. This study attempted to identify the predictive factors and outcome of refractoriness to first-line ICT. All patients diagnosed with stage II to IV follicular lymphoma between 2002 and 2014 and treated with first-line ICT in 4 Spanish institutions were analyzed. Those with no response or progression or relapse within 6 months of first-line response assessment were considered ICT refractory. Three hundred forty-three patients were included (median age 58 years, 48% male), of whom 53 (15%) were ICT refractory. On multivariate analysis, high-risk follicular lymphoma international prognostic index (FLIPI) score, B symptoms, and elevated β2-microglobulin were correlated with refractoriness, and refractoriness, high-risk FLIPI score, and β2-microglobulin were correlated with overall survival (OS). Compared with ICT-sensitive, ICT-refractory patients had a higher incidence of histological transformation (5-year cumulative incidence 25% [14%-39%] vs. 6% [3%-10%], P < .001), a higher rate of refractoriness to second-line therapy (16/33 [48%] vs. 13/57 [23%], P = .01), and a lower OS (5-year OS probability 38% [95% CI 23%-53%] vs. 87% [82%-92%%], P < .001). In conclusion, refractoriness to ICT was seen in 15% of patients and was predicted by high-FLIPI scores, B symptoms, and elevated serum β2-micrglobulin. Immunochemotherapy-refractory patients had a worse prognosis than ICT-sensitive patients, and current treatment options for this subgroup are not satisfactory.

journal_name

Hematol Oncol

journal_title

Hematological oncology

authors

Sorigue M,Mercadal S,Alonso S,Fernández-Álvarez R,García O,Moreno M,Pomares H,Alcoceba M,González-García E,Motlló C,González-Barca E,Martin A,Sureda A,Caballero D,Ribera JM,Sancho JM

doi

10.1002/hon.2378

subject

Has Abstract

pub_date

2017-12-01 00:00:00

pages

520-527

issue

4

eissn

0278-0232

issn

1099-1069

journal_volume

35

pub_type

杂志文章
  • Retinoblastoma protein and Epstein-Barr virus (EBV) expression in South African Hodgkin's disease.

    abstract::The aim of this study was to explore the expression of retinoblastoma protein and EBV status in a cohort of cases of Hodgkin's disease from South Africa. Seventy one cases of Hodgkin's disease were accessed over a 6-year period and were classified according to the Rye Classification. Relevant sections were stained wit...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/(sici)1099-1069(199711)15:4<191::aid-hon61

    authors: Chetty R,Bickhoo A

    更新日期:1997-11-01 00:00:00

  • Intensive retreatment of adults and children with acute lymphoblastic leukemia.

    abstract::Twenty-three patients (16 adults) failing their first or subsequent (n = 8) intensive treatment for de novo acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia lymphoid blast phase (n = 2) were managed with protocol POG 8201, originally introduced in relapsed ALL of childhood. In this programme, a four-dru...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900100206

    authors: Bassan R,Cornelli PE,Battista R,Terzi F,Buelli M,Rambaldi A,Viero P,D'Emilio A,Dini E,Barbui T

    更新日期:1992-03-01 00:00:00

  • Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.

    abstract::The objective of this research was to characterize the venetoclax exposure-efficacy and exposure-safety relationships and determine its optimal dose in elderly patients with newly diagnosed acute myeloid leukemia (AML) receiving venetoclax in combination with low intensity therapies (hypomethylating agent [HMA; azacit...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2646

    authors: Agarwal S,Gopalakrishnan S,Mensing S,Potluri J,Hayslip J,Kirschbrown W,Friedel A,Menon R,Salem AH

    更新日期:2019-10-01 00:00:00

  • Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation.

    abstract::Diffuse large B-cell lymphoma (DLBCL) includes two prognostically important subtypes, the germinal center B-cell (GCB) and the non-GCB types. The aim of this study was to evaluate immunohistochemical approaches for predicting the survival of patients with DLBCL following autologous hematopoietic stem cell transplantat...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.1017

    authors: Gu K,Weisenburger DD,Fu K,Chan WC,Greiner TC,Aoun P,Smith LM,Bast M,Liu Z,Bociek RG,Bierman PJ,Armitage JO,Vose JM

    更新日期:2012-09-01 00:00:00

  • Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy.

    abstract::Among patients with advanced-stage classical Hodgkin lymphoma (cHL) receiving ABVD chemotherapy, PET performed after the first two treatment cycles (PET-2) has prognostic value. However, 15% of patients with a negative PET-2 will experience treatment failure. Here we prospectively evaluated serum thymus and activation...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2775

    authors: Viviani S,Mazzocchi A,Pavoni C,Taverna F,Rossi A,Patti C,Romano A,Trentin L,Sorasio R,Guidetti A,Gottardi D,Tarella C,Cimminiello M,Zanotti R,Farina L,Ferreri AJM,Galbiati M,Corradini P,Gianni AM,Gallamini A,Ramba

    更新日期:2020-10-01 00:00:00

  • Definition of disease-progression risk stratification in untreated chronic lymphocytic leukemia using combined clinical, molecular and virological variables.

    abstract::Prognoses of persons with chronic lymphocytic leukemia (CLL) including time-to-therapy (TTT) and survival is heterogeneous. Risk factors and predictive scoring systems are mostly developed in persons of predominately European descent with CLL. Whether these systems accurately predict TTT and survival of Han Chinese wi...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2520

    authors: Qin S,Fan L,Liang J,Gale R,Miao Y,Wu Y,Wang R,Yang H,Wu W,Xia Y,Wu J,Zhu H,Wang L,Xu W,Li J

    更新日期:2018-10-01 00:00:00

  • BRAFV600E and MAP2K1 mutations in Langerhans cell histiocytosis occur predominantly in children.

    abstract::Langerhans cell histiocytosis (LCH) is a proliferative disease of CD1a+ /CD207+ dendritic cells. Recurrent BRAFV600E and MAP2K1 mutations have been reported in LCH. To investigate the relationship among the mutation, clinical findings, and differentiation status of LCH, respectively, we studied 97 cases of LCH by usin...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2344

    authors: Zeng K,Ohshima K,Liu Y,Zhang W,Wang L,Fan L,Li M,Li X,Wang Z,Guo S,Yan Q,Guo Y

    更新日期:2017-12-01 00:00:00

  • The value of EUS in combination with cytological, flow cytometry, and gene rearrangement in the diagnosis of gastrointestinal lymphoma.

    abstract::Endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration (EUS-FNA) have a great value in clinical practice of gastrointestinal lymphoma (GIL). Auxiliary methods such as flow cytometry (FCM) and gene rearrangement provide additional information for the diagnosis. Current study aims to explore the diagnostic va...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2298

    authors: Yu L,Chen K,Xu Y,Wang S,Liu Q,Ye Q,Ye T,Sun Y

    更新日期:2017-09-01 00:00:00

  • A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma.

    abstract::These are the final results of the Ofatumumab in MALT lymphoma study (O-MA 1), a pilot phase II trial evaluating the capacity and safety of ofatumumab to induce objective responses in patients with Helicobacter pylori eradication refractory or extragastric MALT lymphoma. Ofatumumab was given at 4 weekly doses (1000 mg...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2454

    authors: Kiesewetter B,Neuper O,Mayerhoefer ME,Dolak W,Lukas J,Simonitsch-Klupp I,Raderer M

    更新日期:2018-02-01 00:00:00

  • A double-blind, randomized, controlled trial on N-acetylcysteine for the prevention of acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation.

    abstract::Acute kidney injury (AKI) is one of the complications of hematopoietic stem cell transplantation and is associated with increased mortality. N-acetylcysteine (NAC) is a thiol compound with antioxidant and vasodilatory properties that has been investigated for the prevention of AKI in several clinical settings. In the ...

    journal_title:Hematological oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/hon.2141

    authors: Ataei S,Hadjibabaie M,Moslehi A,Taghizadeh-Ghehi M,Ashouri A,Amini E,Gholami K,Hayatshahi A,Vaezi M,Ghavamzadeh A

    更新日期:2015-06-01 00:00:00

  • CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma.

    abstract::From 1991 to 1997, we have treated 78 newly diagnosed patients with aggressive non-Hodgkin's lymphoma with a modified CHOP regimen in which epirubicin (60 mg/m2) was used in place of doxorubicin (50 mg/m2), i.e. CEOP (cyclophosphamide, epirubicin, vincristine and prednisolone). The median age was 41 years (range: 17 t...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/(sici)1099-1069(199809)16:3<117::aid-hon63

    authors: Chim CS,Kwong YL,Lie AK,Lee CK,Liang R

    更新日期:1998-09-01 00:00:00

  • The sulfone syndrome secondary to dapsone prophylaxis in a patient undergoing unrelated hematopoietic stem cell transplantation.

    abstract::Dapsone is commonly used for pneumocystis carinii pneumonia (PCP) prophylaxis in immunocompromised patients. It has been used as an alternative therapy in the hematopoietic stem cell transplant (HSCT) setting in patients who can't tolerate trimethoprim-sulfamethoxazole. The Sulfone syndrome is not a well-known sequela...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.780

    authors: Abidi MH,Kozlowski JR,Ibrahim RB,Peres E

    更新日期:2006-09-01 00:00:00

  • Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide.

    abstract::Cytokine release syndrome (CRS) is a systemic inflammatory response with aberrant immune activation and immune hyperstimulation, that leads to increased cytokine levels and inflammation. CRS has been described after antibody and cellular-based therapies. The use of posttransplant cyclophosphamide (PTCy) as graft-vs-ho...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2772

    authors: Solán L,Landete E,Bailén R,Dorado N,Oarbeascoa G,Anguita J,Díez-Martín JL,Kwon M

    更新日期:2020-10-01 00:00:00

  • R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study.

    abstract::Several studies have shown that adding rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or reducing the interval between chemotherapy cycles from 3 weeks to 2 weeks improves survival in patients with diffuse large B-cell lymphoma (DLBCL). These studies prompted our group (GOTEL) to evaluate...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.829

    authors: Rueda A,Sabin P,Rifá J,Llanos M,Gómez-Codina J,Lobo F,García R,Herrero J,Provencio M,Jara C,Grupo Oncológico para el Tratamiento y Estudio de los Linfomas (GOTEL).

    更新日期:2008-03-01 00:00:00

  • The more basic isoform of eEF1A relates to tumour cell phenotype and is modulated by hyper-proliferative/differentiating stimuli in normal lymphocytes and CCRF-CEM T-lymphoblasts.

    abstract::The elongation factor 1A proteins (eEF1A1/A2) are known to play a role in tumours. We previously found that a more basic isoform of eEF1A (MBI-eEF1A) is present in the cytoskeletal/nuclear-enriched extracts of CCRF-CEM T-lymphoblasts but not in those of normal lymphocytes. To obtain deeper knowledge about MBI-eEF1A bi...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2022

    authors: Scaggiante B,Dapas B,Pozzato G,Grassi G

    更新日期:2013-06-01 00:00:00

  • Large cell lymphoma with initial presentation in the bone marrow.

    abstract::This report describes 14 cases of large cell lymphoma with initial presentation as marrow involvement in the absence of peripheral lymphadenopathy. The disease affected mainly the middle-aged and elderly, with male predominance. Most patients presented with swinging fever and peripheral blood cytopenia. Reactive hemop...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900100504

    authors: Wong KF,Chan JK,Ng CS,Chu YC,Li LP,Chan CH

    更新日期:1992-09-01 00:00:00

  • Protein kinase C isozyme expression in human leukemia-lymphoma cell lines--an immunocytochemical study.

    abstract::There have been an increasing number of reports describing a pivotal role for phosphorylation in cellular responses for cell differentiation and proliferation. We examined an immunocytochemical expression of protein kinase C(PKC) isozymes (type I, II, and III) in 22 leukemia-lymphoma cell lines. Of these cell lines, 2...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900100602

    authors: Hojo H,Morimura Y,Abe M,Tominaga K,Nozawa Y,Nakamura N,Ono N,Tasaki K,Yamaguchi Y,Suzuki S

    更新日期:1992-11-01 00:00:00

  • A controversial issue: could a watch-and-wait policy for patients with non-Hodgkin's lymphoma clinical stage I or IE with no lymphoma left following diagnostic surgery be justified? Results of a single centre study.

    abstract:BACKGROUND:A subset of patients with non-Hodgkin's lymphoma (NHL) with clinical stage I or IE at presentation is left without other NHL localizations following surgery performed for diagnostic histology, and thus without any target lesion to judge the immediate effectiveness of immediately applied additional treatment ...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/(sici)1099-1069(199705)15:2<53::aid-hon598

    authors: Jelić S,Frim O,Gligorijević G,Gavrilović D,Manojlović N,Jovanović V,Oprić M

    更新日期:1997-05-01 00:00:00

  • Relationship between myeloblasts and cluster-forming cells in acute non-lymphocytic leukemia.

    abstract::The relationship between myeloblast-like cells and cluster-forming cells detected by growth in agar has been studied in 22 untreated patients with acute non-lymphocytic leukemia by means of comparing data for 3H-TdR labelling of myeloblast-like cells and 3H-TdR suiciding of cluster-forming cells. The fraction of myelo...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900020210

    authors: Gustavsson A,Olofsson T,Olsson I

    更新日期:1984-04-01 00:00:00

  • On point in primary CNS lymphoma.

    abstract::Primary CNS lymphoma (PCNSL) is an aggressive brain tumor that represents a significant challenge both to elucidate its biological pathogenesis as well as to develop definitive precision medicines with minimal collateral toxicity. We highlight the key issues in diagnosis and treatment and focus on emerging technologie...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2761

    authors: Tsang M,Cleveland J,Rubenstein JL

    更新日期:2020-12-01 00:00:00

  • Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy.

    abstract::We verified whether early resistance to treatment can be predicted in a subset of patients with very favourable, early stage Hodgkin lymphoma, treated with VBM (vinblastine, bleomycin and methotrexate) chemotherapy and involved-field radiotherapy, an effective combination with very low early and late toxicity. The rel...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2035

    authors: Gobbi PG,Bergonzi M,Bassi E,Merli F,Coriani C,Federico M

    更新日期:2013-09-01 00:00:00

  • Improved survival of older patients with multiple myeloma in the era of novel agents.

    abstract::Multiple myeloma (MM) is the most common hematologic malignancy in Europe. Although remaining an incurable disease, substantial progress has been made within the last two decades. However, until recently, improvement in overall survival (OS) was only documented in younger, transplant-eligible patients. In this analysi...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2205

    authors: Mey UJ,Leitner C,Driessen C,Cathomas R,Klingbiel D,Hitz F

    更新日期:2016-12-01 00:00:00

  • Auer rods in the acute myeloid leukemias: frequency and methods of demonstration.

    abstract::One hundred and twenty-five cases of acute myeloid leukemia (AML) were reviewed for the presence of Auer rods by two peroxidase methods. The percentage of Auer rods recognized by Wright-Giemsa (WG) staining was 20.8% but three times higher by peroxidase staining techniques using either benzidine base as a substrate (P...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900050306

    authors: Jain NC,Cox C,Bennett JM

    更新日期:1987-07-01 00:00:00

  • Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or NF-κB signalling instead of B-cell receptor signalling.

    abstract::Post-transplant lymphoproliferative disorders (PTLD) are a major problem in transplant medicine. So far, the insights into pathogenesis and potentially druggable pathways in PTLD remain scarce. We investigated a cohort of PTLD patients, consisting of both polymorphic (n = 3) and monomorphic (n = 19) B-cell lymphoproli...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2280

    authors: Menter T,Dickenmann M,Juskevicius D,Steiger J,Dirnhofer S,Tzankov A

    更新日期:2017-06-01 00:00:00

  • Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study.

    abstract::Bone marrow (BM) trephine biopsy is a part of routine staging of patients with newly diagnosed diffuse large B cell lymphoma (DLBCL). The significance of lymphoid monoclonal population on flow cytometry (FC) of the BM aspirate in the presence of negative BM histology has not been clarified. In this study, we assessed ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2127

    authors: Wolach O,Fraser A,Luchiansky M,Shapiro C,Radnay J,Shpilberg O,Lishner M,Lahav M

    更新日期:2015-03-01 00:00:00

  • Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/MYC rearrangement in Japan.

    abstract::The prognosis of diffuse large B-cell lymphoma (DLBCL) having MYC rearrangement (MYC-R), including double hit lymphoma (DHL), is poor by standard immunochemotherapy. To evaluate the significance of hematopoietic stem cell transplantation (SCT) for DLBCL with MYC-R, we retrospectively analyzed Japanese SCT registry dat...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2811

    authors: Takahashi T,Suzuki R,Yamamoto G,Nakazawa H,Kurosawa M,Kobayashi T,Okada M,Akasaka T,Kim SW,Fukuda T,Ichinohe T,Atsuta Y,Suzumiya J

    更新日期:2020-09-26 00:00:00

  • Influence of ethnicity and improved outcome of acute myeloid leukaemia: two decades of follow-up of Israeli patient cohort.

    abstract::Acute myeloid leukaemia is a disease with unfavourable prognosis. The significance of various prognostic parameters is not fully understood. We studied 293 patients to examine the influence of ethnicity and molecular markers. The median survival for all patients was correlated with age, white blood cell count and kary...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2092

    authors: Goldschmidt N,Cohen SB,Gatt ME,Safrai M,Rund D

    更新日期:2014-06-01 00:00:00

  • Comparison of 60 and 80 mg/m2 of daunorubicin in induction therapy of acute myeloid leukaemia.

    abstract::For finding better method of acute myeloid leukaemia (AML) induction, we designed a prospective clinical trial to find a more effective regimen with least toxicity for induction therapy of AML. Hence, we examined different accepted doses of daunorubicin and their outcomes. Total of 114 patients were included in the st...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/hon.2236

    authors: Vaezi M,Bahar B,Mousavi A,Yaghmai M,Kasaeian A,Souri M,Jahani M,Alimoghaddam K,Ghavamzadeh A

    更新日期:2017-03-01 00:00:00

  • In vitro maturation is a viable option for urgent fertility preservation in young women with hematological conditions.

    abstract::Fertility preservation embraces different techniques developed to improve young women chances of becoming mothers after healing. Among them, in vitro maturation (IVM) procedure is based on oocyte retrieval without any gonadotropin treatment, feasible under locoregional or local anesthesia, with very low operative comp...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2724

    authors: Sonigo C,Bajeux J,Boubaya M,Eustache F,Sifer C,Lévy V,Grynberg M,Sermondade N

    更新日期:2020-10-01 00:00:00

  • Whole-body magnetic resonance imaging (WB-MRI) in lymphoma: State of the art.

    abstract::The improvements in magnetic resonance imaging (MRI) technology and the concern related to the increased cancer risk in patients with lymphoma, also due to radiation exposure associated with imaging examinations, have led to the introduction of whole-body MRI (WB-MRI) as a radiation-free alternative to standard imagin...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2676

    authors: Albano D,Bruno A,Patti C,Micci G,Midiri M,Tarella C,Galia M

    更新日期:2020-02-01 00:00:00